ASXL1 Mutations Are Associated with a Response to Alvocidib and 5-Azacytidine Combination in Myelodysplastic Neoplasms

Mutational profiling of myelodysplastic syndromes (MDS) samples identified ASXL1 mutations as predictors of response. Further, increased response rates were associated with higher gene-expression of the pro-apoptotic factor NOXA in ASXL1 mutated samples.